Concepts (236)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Bipolar Disorder | 37 | 2026 | 346 | 7.980 |
Why?
|
| Antidepressive Agents | 7 | 2026 | 319 | 1.710 |
Why?
|
| Antipsychotic Agents | 8 | 2024 | 375 | 1.320 |
Why?
|
| Temperament | 3 | 2025 | 31 | 1.130 |
Why?
|
| Suicidal Ideation | 7 | 2025 | 251 | 1.110 |
Why?
|
| Suicide | 5 | 2024 | 206 | 1.080 |
Why?
|
| Depressive Disorder | 4 | 2019 | 460 | 1.040 |
Why?
|
| Lithium Compounds | 3 | 2020 | 13 | 0.910 |
Why?
|
| Antimanic Agents | 5 | 2023 | 34 | 0.850 |
Why?
|
| Genital Neoplasms, Female | 1 | 2024 | 43 | 0.830 |
Why?
|
| Emotions | 4 | 2023 | 349 | 0.810 |
Why?
|
| Hippocampus | 6 | 2019 | 794 | 0.740 |
Why?
|
| Neoplasms | 3 | 2026 | 2986 | 0.730 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2026 | 814 | 0.660 |
Why?
|
| Depression | 8 | 2026 | 1315 | 0.650 |
Why?
|
| Facial Expression | 1 | 2019 | 22 | 0.580 |
Why?
|
| Attention | 2 | 2020 | 191 | 0.560 |
Why?
|
| Mood Disorders | 5 | 2026 | 129 | 0.560 |
Why?
|
| Anxiety | 4 | 2024 | 1010 | 0.550 |
Why?
|
| Lithium | 2 | 2023 | 66 | 0.530 |
Why?
|
| Magnetic Resonance Imaging | 15 | 2023 | 3752 | 0.490 |
Why?
|
| Substance-Related Disorders | 3 | 2022 | 497 | 0.470 |
Why?
|
| Cerebral Cortex | 1 | 2019 | 445 | 0.470 |
Why?
|
| Antineoplastic Agents | 1 | 2026 | 1815 | 0.470 |
Why?
|
| Humans | 61 | 2026 | 130534 | 0.470 |
Why?
|
| Benzodiazepines | 2 | 2013 | 107 | 0.460 |
Why?
|
| Dopamine Plasma Membrane Transport Proteins | 2 | 2026 | 32 | 0.440 |
Why?
|
| Child Abuse | 3 | 2026 | 227 | 0.430 |
Why?
|
| Resilience, Psychological | 2 | 2026 | 84 | 0.420 |
Why?
|
| Amygdala | 3 | 2021 | 73 | 0.420 |
Why?
|
| Psychiatric Status Rating Scales | 9 | 2026 | 829 | 0.420 |
Why?
|
| Adult Survivors of Child Adverse Events | 2 | 2026 | 15 | 0.380 |
Why?
|
| Adult Survivors of Child Abuse | 2 | 2026 | 14 | 0.370 |
Why?
|
| Adult | 27 | 2026 | 31114 | 0.360 |
Why?
|
| Adolescent | 15 | 2025 | 20889 | 0.360 |
Why?
|
| Female | 37 | 2026 | 70545 | 0.360 |
Why?
|
| Breast Neoplasms | 1 | 2024 | 2596 | 0.360 |
Why?
|
| Impulsive Behavior | 3 | 2025 | 161 | 0.340 |
Why?
|
| Antidepressive Agents, Tricyclic | 2 | 2025 | 28 | 0.340 |
Why?
|
| Anhedonia | 3 | 2026 | 38 | 0.330 |
Why?
|
| Inflammatory Bowel Diseases | 2 | 2025 | 324 | 0.320 |
Why?
|
| Middle Aged | 19 | 2026 | 28408 | 0.310 |
Why?
|
| Child | 16 | 2026 | 26263 | 0.310 |
Why?
|
| Male | 30 | 2026 | 64613 | 0.310 |
Why?
|
| Neuroimaging | 5 | 2021 | 384 | 0.300 |
Why?
|
| Gray Matter | 3 | 2020 | 50 | 0.300 |
Why?
|
| Stress Disorders, Post-Traumatic | 2 | 2025 | 639 | 0.280 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 6 | 2024 | 226 | 0.270 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 2 | 2026 | 96 | 0.260 |
Why?
|
| Dopamine | 2 | 2026 | 244 | 0.260 |
Why?
|
| Marijuana Abuse | 2 | 2022 | 52 | 0.260 |
Why?
|
| White Matter | 2 | 2022 | 219 | 0.260 |
Why?
|
| Psychotropic Drugs | 3 | 2025 | 122 | 0.250 |
Why?
|
| Anxiety Disorders | 2 | 2025 | 730 | 0.240 |
Why?
|
| Organ Size | 5 | 2019 | 408 | 0.240 |
Why?
|
| Drug Resistance, Multiple | 1 | 2026 | 53 | 0.230 |
Why?
|
| Serotonin and Noradrenaline Reuptake Inhibitors | 1 | 2025 | 15 | 0.230 |
Why?
|
| Child of Impaired Parents | 1 | 2025 | 20 | 0.230 |
Why?
|
| Psychopharmacology | 1 | 2025 | 14 | 0.230 |
Why?
|
| Corpus Striatum | 1 | 2026 | 95 | 0.230 |
Why?
|
| Irritable Mood | 1 | 2025 | 10 | 0.220 |
Why?
|
| Psychological Trauma | 1 | 2025 | 28 | 0.220 |
Why?
|
| Mental Disorders | 3 | 2024 | 906 | 0.220 |
Why?
|
| Self-Injurious Behavior | 2 | 2024 | 67 | 0.210 |
Why?
|
| Cross-Sectional Studies | 6 | 2026 | 3812 | 0.210 |
Why?
|
| Putamen | 1 | 2024 | 24 | 0.210 |
Why?
|
| Aged | 8 | 2025 | 20885 | 0.210 |
Why?
|
| Seasons | 1 | 2026 | 335 | 0.210 |
Why?
|
| Milk Banks | 1 | 2023 | 4 | 0.200 |
Why?
|
| Abnormalities, Drug-Induced | 1 | 2024 | 84 | 0.200 |
Why?
|
| Cyclothymic Disorder | 1 | 2023 | 3 | 0.200 |
Why?
|
| Pyrroles | 1 | 2024 | 188 | 0.190 |
Why?
|
| Stress, Psychological | 2 | 2020 | 532 | 0.190 |
Why?
|
| Brain | 4 | 2021 | 3167 | 0.190 |
Why?
|
| Piperidines | 1 | 2024 | 221 | 0.190 |
Why?
|
| Trazodone | 1 | 2022 | 6 | 0.190 |
Why?
|
| Quinolones | 2 | 2013 | 58 | 0.180 |
Why?
|
| Cognition | 3 | 2023 | 822 | 0.180 |
Why?
|
| Suicide, Attempted | 3 | 2019 | 150 | 0.180 |
Why?
|
| Cannabis | 1 | 2022 | 50 | 0.170 |
Why?
|
| Endophenotypes | 1 | 2021 | 14 | 0.170 |
Why?
|
| Depressive Disorder, Treatment-Resistant | 1 | 2023 | 131 | 0.170 |
Why?
|
| Pyrimidines | 1 | 2024 | 448 | 0.170 |
Why?
|
| Case-Control Studies | 7 | 2026 | 3353 | 0.170 |
Why?
|
| Hallucinogens | 1 | 2022 | 67 | 0.170 |
Why?
|
| Aggression | 2 | 2021 | 218 | 0.160 |
Why?
|
| Piperazines | 2 | 2013 | 265 | 0.160 |
Why?
|
| Milk, Human | 1 | 2023 | 319 | 0.160 |
Why?
|
| Yoga | 1 | 2020 | 13 | 0.160 |
Why?
|
| Meditation | 1 | 2020 | 20 | 0.160 |
Why?
|
| Young Adult | 8 | 2025 | 10037 | 0.160 |
Why?
|
| Pituitary-Adrenal System | 1 | 2019 | 33 | 0.150 |
Why?
|
| Nucleus Accumbens | 1 | 2020 | 55 | 0.150 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 2019 | 57 | 0.150 |
Why?
|
| Happiness | 1 | 2019 | 11 | 0.150 |
Why?
|
| Body Mass Index | 1 | 2025 | 1701 | 0.140 |
Why?
|
| Atrophy | 2 | 2016 | 247 | 0.140 |
Why?
|
| Evoked Potentials | 1 | 2019 | 112 | 0.140 |
Why?
|
| Quality of Life | 2 | 2025 | 2072 | 0.140 |
Why?
|
| Electroencephalography | 1 | 2023 | 858 | 0.140 |
Why?
|
| Fear | 1 | 2019 | 190 | 0.130 |
Why?
|
| Retrospective Studies | 7 | 2026 | 17634 | 0.130 |
Why?
|
| Bayes Theorem | 1 | 2019 | 307 | 0.130 |
Why?
|
| Neuropsychological Tests | 1 | 2021 | 953 | 0.130 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2020 | 248 | 0.130 |
Why?
|
| Risk Factors | 4 | 2026 | 11013 | 0.130 |
Why?
|
| Circadian Rhythm | 1 | 2019 | 319 | 0.130 |
Why?
|
| Life Change Events | 1 | 2017 | 59 | 0.130 |
Why?
|
| Psychomotor Agitation | 2 | 2014 | 57 | 0.120 |
Why?
|
| Time | 1 | 2016 | 92 | 0.120 |
Why?
|
| Psychological Tests | 1 | 2016 | 86 | 0.120 |
Why?
|
| Italy | 3 | 2025 | 109 | 0.120 |
Why?
|
| Prenatal Exposure Delayed Effects | 2 | 2024 | 235 | 0.120 |
Why?
|
| Treatment Outcome | 5 | 2025 | 12846 | 0.120 |
Why?
|
| Models, Neurological | 1 | 2017 | 211 | 0.110 |
Why?
|
| Tropanes | 2 | 2026 | 2 | 0.110 |
Why?
|
| Neuroprotective Agents | 1 | 2016 | 157 | 0.110 |
Why?
|
| Animals | 3 | 2026 | 33726 | 0.090 |
Why?
|
| Memantine | 1 | 2012 | 17 | 0.090 |
Why?
|
| Histrionic Personality Disorder | 1 | 2012 | 1 | 0.090 |
Why?
|
| Factitious Disorders | 1 | 2012 | 2 | 0.090 |
Why?
|
| Chernobyl Nuclear Accident | 1 | 2012 | 5 | 0.090 |
Why?
|
| Excitatory Amino Acid Antagonists | 1 | 2012 | 83 | 0.090 |
Why?
|
| Reproducibility of Results | 4 | 2021 | 2896 | 0.090 |
Why?
|
| Panic Disorder | 1 | 2012 | 53 | 0.090 |
Why?
|
| Malformations of Cortical Development | 1 | 2012 | 60 | 0.090 |
Why?
|
| Surveys and Questionnaires | 4 | 2026 | 4058 | 0.090 |
Why?
|
| Stalking | 1 | 2011 | 4 | 0.080 |
Why?
|
| Arnold-Chiari Malformation | 1 | 2012 | 51 | 0.080 |
Why?
|
| Sandfly fever Naples virus | 1 | 2010 | 1 | 0.080 |
Why?
|
| Bunyaviridae Infections | 1 | 2010 | 6 | 0.080 |
Why?
|
| Electroconvulsive Therapy | 1 | 2012 | 82 | 0.080 |
Why?
|
| Meningitis, Aseptic | 1 | 2010 | 12 | 0.080 |
Why?
|
| Encephalitis, Viral | 1 | 2010 | 20 | 0.080 |
Why?
|
| Clozapine | 1 | 2010 | 24 | 0.080 |
Why?
|
| Chromatography, Liquid | 1 | 2012 | 233 | 0.080 |
Why?
|
| Disruptive, Impulse Control, and Conduct Disorders | 1 | 2010 | 33 | 0.080 |
Why?
|
| Prospective Studies | 3 | 2024 | 6424 | 0.080 |
Why?
|
| Cytochrome P-450 CYP1A2 | 1 | 2010 | 47 | 0.080 |
Why?
|
| Psychotic Disorders | 1 | 2012 | 146 | 0.080 |
Why?
|
| Biomarkers | 1 | 2019 | 3367 | 0.080 |
Why?
|
| Disease Progression | 1 | 2016 | 2195 | 0.080 |
Why?
|
| Pancreatitis | 1 | 2010 | 139 | 0.070 |
Why?
|
| Personality | 1 | 2010 | 110 | 0.070 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2012 | 287 | 0.070 |
Why?
|
| Double-Blind Method | 2 | 2023 | 1613 | 0.070 |
Why?
|
| Psychometrics | 2 | 2025 | 677 | 0.070 |
Why?
|
| Gyrus Cinguli | 2 | 2023 | 131 | 0.070 |
Why?
|
| Longitudinal Studies | 2 | 2025 | 1485 | 0.070 |
Why?
|
| Inpatients | 1 | 2011 | 561 | 0.060 |
Why?
|
| Comorbidity | 2 | 2026 | 1589 | 0.060 |
Why?
|
| Cerebellum | 2 | 2023 | 441 | 0.060 |
Why?
|
| Temporal Lobe | 2 | 2019 | 110 | 0.060 |
Why?
|
| Child, Preschool | 1 | 2019 | 15045 | 0.050 |
Why?
|
| Anisotropy | 1 | 2022 | 117 | 0.050 |
Why?
|
| Aripiprazole | 2 | 2013 | 22 | 0.050 |
Why?
|
| Mice | 1 | 2019 | 18198 | 0.050 |
Why?
|
| Corpus Callosum | 1 | 2022 | 104 | 0.050 |
Why?
|
| Breast Feeding | 1 | 2023 | 238 | 0.040 |
Why?
|
| Sex Factors | 1 | 2025 | 1348 | 0.040 |
Why?
|
| Calcium Channels, L-Type | 1 | 2021 | 50 | 0.040 |
Why?
|
| Diffusion Tensor Imaging | 1 | 2022 | 255 | 0.040 |
Why?
|
| Communicable Disease Control | 1 | 2022 | 139 | 0.040 |
Why?
|
| Pregnancy Outcome | 1 | 2024 | 618 | 0.040 |
Why?
|
| Mothers | 1 | 2023 | 385 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2024 | 1440 | 0.040 |
Why?
|
| Ketamine | 1 | 2023 | 206 | 0.040 |
Why?
|
| Factor Analysis, Statistical | 1 | 2020 | 236 | 0.040 |
Why?
|
| Health | 1 | 2019 | 35 | 0.040 |
Why?
|
| Reward | 1 | 2020 | 130 | 0.040 |
Why?
|
| Age Factors | 2 | 2016 | 2822 | 0.030 |
Why?
|
| Pregnancy Complications | 1 | 2024 | 564 | 0.030 |
Why?
|
| Anticonvulsants | 2 | 2011 | 363 | 0.030 |
Why?
|
| Students | 1 | 2020 | 250 | 0.030 |
Why?
|
| Combined Modality Therapy | 2 | 2012 | 1212 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2023 | 1263 | 0.030 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2023 | 914 | 0.030 |
Why?
|
| Self Report | 1 | 2020 | 553 | 0.030 |
Why?
|
| Interview, Psychological | 1 | 2017 | 101 | 0.030 |
Why?
|
| Rest | 1 | 2017 | 64 | 0.030 |
Why?
|
| Pregnancy | 2 | 2024 | 7459 | 0.030 |
Why?
|
| Internal Capsule | 1 | 2016 | 47 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2017 | 927 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2024 | 5049 | 0.030 |
Why?
|
| Thalamus | 1 | 2016 | 93 | 0.030 |
Why?
|
| Pandemics | 1 | 2022 | 1116 | 0.030 |
Why?
|
| Genome-Wide Association Study | 1 | 2021 | 1829 | 0.020 |
Why?
|
| Diagnosis, Dual (Psychiatry) | 1 | 2013 | 22 | 0.020 |
Why?
|
| Time Factors | 2 | 2013 | 6175 | 0.020 |
Why?
|
| Hospitals, University | 1 | 2013 | 103 | 0.020 |
Why?
|
| Follow-Up Studies | 2 | 2013 | 5187 | 0.020 |
Why?
|
| Injections, Intramuscular | 1 | 2013 | 185 | 0.020 |
Why?
|
| Machiavellianism | 1 | 2012 | 2 | 0.020 |
Why?
|
| Munchausen Syndrome by Proxy | 1 | 2012 | 5 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2012 | 148 | 0.020 |
Why?
|
| Septum of Brain | 1 | 2012 | 4 | 0.020 |
Why?
|
| Solid Phase Extraction | 1 | 2012 | 4 | 0.020 |
Why?
|
| Locus Coeruleus | 1 | 2012 | 20 | 0.020 |
Why?
|
| Forensic Psychiatry | 1 | 2012 | 15 | 0.020 |
Why?
|
| Muscle Relaxants, Central | 1 | 2012 | 36 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2021 | 2827 | 0.020 |
Why?
|
| Prodromal Symptoms | 1 | 2012 | 10 | 0.020 |
Why?
|
| Limit of Detection | 1 | 2012 | 73 | 0.020 |
Why?
|
| Calibration | 1 | 2012 | 92 | 0.020 |
Why?
|
| Romania | 1 | 2011 | 3 | 0.020 |
Why?
|
| Reactive Attachment Disorder | 1 | 2011 | 4 | 0.020 |
Why?
|
| Lithium Carbonate | 1 | 2011 | 20 | 0.020 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2012 | 80 | 0.020 |
Why?
|
| Reference Standards | 1 | 2012 | 231 | 0.020 |
Why?
|
| Schizophrenia, Paranoid | 1 | 2010 | 10 | 0.020 |
Why?
|
| Gliosis | 1 | 2010 | 31 | 0.020 |
Why?
|
| Endemic Diseases | 1 | 2010 | 60 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2024 | 8626 | 0.020 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2012 | 102 | 0.020 |
Why?
|
| Valproic Acid | 1 | 2011 | 140 | 0.020 |
Why?
|
| Epilepsies, Partial | 1 | 2010 | 85 | 0.020 |
Why?
|
| Schizophrenia | 1 | 2013 | 324 | 0.020 |
Why?
|
| Patient Admission | 1 | 2011 | 185 | 0.020 |
Why?
|
| Occupational Exposure | 1 | 2010 | 135 | 0.020 |
Why?
|
| Behavior Therapy | 1 | 2012 | 272 | 0.020 |
Why?
|
| Sex Characteristics | 1 | 2011 | 321 | 0.020 |
Why?
|
| Psychotherapy | 1 | 2012 | 247 | 0.020 |
Why?
|
| Syndrome | 1 | 2012 | 1156 | 0.020 |
Why?
|
| Sexual Behavior | 1 | 2010 | 232 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2017 | 3038 | 0.020 |
Why?
|
| Hyperglycemia | 1 | 2010 | 233 | 0.020 |
Why?
|
| Logistic Models | 1 | 2013 | 1796 | 0.020 |
Why?
|
| Medication Adherence | 1 | 2012 | 337 | 0.020 |
Why?
|
| Personality Disorders | 1 | 2011 | 175 | 0.020 |
Why?
|
| Infant | 1 | 2023 | 13318 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2012 | 1122 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2017 | 6771 | 0.010 |
Why?
|
| Genotype | 1 | 2010 | 2590 | 0.010 |
Why?
|
| Antibodies, Viral | 1 | 2010 | 1171 | 0.010 |
Why?
|
| Hospitalization | 1 | 2013 | 1942 | 0.010 |
Why?
|
| Prevalence | 1 | 2010 | 2692 | 0.010 |
Why?
|